Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alison M Schram

Showing results (31-40 of 75) with videos related to

Pageof 8
Sort By:
Nature Genetics|March 17, 2009
A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasmsOuti Kilpivaara, Semanti Mukherjee, Alison M Schram, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 25, 2019
TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver MutationsEzra Y Rosen, Debra A Goldman, Jaclyn F Hechtman, et al.
Biorxiv : the Preprint Server for Biology|February 23, 2026
Coexistent <i>PTEN</i> and <i>PIK3CA</i> alterations hyperactivate mTORC1 signaling in endometrial cancers and cause their selective sensitivity to mTORC1 inhibitionHilla Solomon, Radha Mukherjee, Yu Chi Yang, et al.
Clinical Genitourinary Cancer|June 1, 2017
Genomic Characterization of Renal Medullary Carcinoma and Treatment OutcomesMaria I Carlo, Joshua Chaim, Sujata Patil, et al.
Future Oncology (London, England)|February 13, 2024
The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring <i>NRG1</i> gene fusionsDong-Wan Kim, Alison M Schram, Antoine Hollebecque, et al.
Molecular Cancer Therapeutics|March 5, 2022
CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 HeterodimerizationLisa Werr, Dennis Plenker, Marcel A Dammert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 28, 2019
High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation BurdenRyma Benayed, Michael Offin, Kerry Mullaney, et al.
Nature Communications|November 23, 2022
Reversion mutations in germline BRCA1/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologiesYonina R Murciano-Goroff, Alison M Schram, Ezra Y Rosen, et al.
Cancer Research|January 16, 2019
Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase FusionsEmiliano Cocco, Jamal Benhamida, Sumit Middha, et al.
The New England Journal of Medicine|February 25, 2026
Phase 1 Study of Rezatapopt, a p53 Reactivator, in <i>TP53</i> Y220C-Mutated TumorsEcaterina E Dumbrava, Geoffrey I Shapiro, Aparna R Parikh, et al.
Pageof 8

Showing results (31-40 of 75) with videos related to

Sort By:
Pageof 8
Nature Genetics|March 17, 2009
A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasmsOuti Kilpivaara, Semanti Mukherjee, Alison M Schram, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 25, 2019
TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver MutationsEzra Y Rosen, Debra A Goldman, Jaclyn F Hechtman, et al.
Biorxiv : the Preprint Server for Biology|February 23, 2026
Coexistent <i>PTEN</i> and <i>PIK3CA</i> alterations hyperactivate mTORC1 signaling in endometrial cancers and cause their selective sensitivity to mTORC1 inhibitionHilla Solomon, Radha Mukherjee, Yu Chi Yang, et al.
Clinical Genitourinary Cancer|June 1, 2017
Genomic Characterization of Renal Medullary Carcinoma and Treatment OutcomesMaria I Carlo, Joshua Chaim, Sujata Patil, et al.
Future Oncology (London, England)|February 13, 2024
The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring <i>NRG1</i> gene fusionsDong-Wan Kim, Alison M Schram, Antoine Hollebecque, et al.
Molecular Cancer Therapeutics|March 5, 2022
CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 HeterodimerizationLisa Werr, Dennis Plenker, Marcel A Dammert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 28, 2019
High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation BurdenRyma Benayed, Michael Offin, Kerry Mullaney, et al.
Nature Communications|November 23, 2022
Reversion mutations in germline BRCA1/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologiesYonina R Murciano-Goroff, Alison M Schram, Ezra Y Rosen, et al.
Cancer Research|January 16, 2019
Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase FusionsEmiliano Cocco, Jamal Benhamida, Sumit Middha, et al.
The New England Journal of Medicine|February 25, 2026
Phase 1 Study of Rezatapopt, a p53 Reactivator, in <i>TP53</i> Y220C-Mutated TumorsEcaterina E Dumbrava, Geoffrey I Shapiro, Aparna R Parikh, et al.
Pageof 8